Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00273312
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2006-01-04
Brief Title:
Patupilone Activity in AdvancedMetastatic Hepatocellular Carcinoma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Phase II Trial of Patupilone EPO906 as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable andor Metastatic Hepatocellular Carcinoma HCC
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety efficacy and activity of patupilone in patients with advanced unresectable andor metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None